Lilly Expands Partnership With China’s Novast

Building on an earlier 2012 agreement, Lilly intends to invest US$60-70 million in Chinese generics manufacturer Novast.

AsianScientist (Mar. 11, 2014) – Lilly and Novast Laboratories Ltd. (Novast) have commenced the expansion of manufacturing and development facility capacities in Nantong, Jiangsu, China.

The facility will be located on a 22-acre campus located inside the Free Trade Zone of the Nantong Economic Technology Development Area (NETDA). The upcoming facility will be built employing a quality by design approach, designed by the world’s leading engineering consultants and is a direct culmination of a synergistic teamwork between Lilly and Novast personnel.

“This day marks a new chapter for Novast as we are transitioning from commercializing quality prescription products in the United States to focusing on catering the same to the China domestic needs through the collaboration platform with Lilly,” said Dr. Zhang, President and CEO of Novast Holdings, Ltd.

The expansion will involve the addition of a 260,000 square foot manufacturing facility, enabling the production of both sustained release and containment solid oral dosage prescription pharmaceuticals with an annual additional capacity of more than 2.2 billion units. The company plans to invest US$60 – 70 million and is anticipated to complete construction by the end of 2015.


Source: Lilly.

Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist